Response: Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study (Diabetes Metab J 2019;43:640–8)

Detalles Bibliográficos
Autores principales: Chung, Yoo-Ri, Ha, Kyoung Hwa, Lee, Kihwang, Kim, Dae Jung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Diabetes Association 2019
Materias:
Response
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6943258/
https://www.ncbi.nlm.nih.gov/pubmed/31902152
http://dx.doi.org/10.4093/dmj.2019.0216
_version_ 1783484851312132096
author Chung, Yoo-Ri
Ha, Kyoung Hwa
Lee, Kihwang
Kim, Dae Jung
author_facet Chung, Yoo-Ri
Ha, Kyoung Hwa
Lee, Kihwang
Kim, Dae Jung
author_sort Chung, Yoo-Ri
collection PubMed
description
format Online
Article
Text
id pubmed-6943258
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Korean Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-69432582020-01-09 Response: Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study (Diabetes Metab J 2019;43:640–8) Chung, Yoo-Ri Ha, Kyoung Hwa Lee, Kihwang Kim, Dae Jung Diabetes Metab J Response Korean Diabetes Association 2019-12 2019-12-26 /pmc/articles/PMC6943258/ /pubmed/31902152 http://dx.doi.org/10.4093/dmj.2019.0216 Text en Copyright © 2019 Korean Diabetes Association http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Response
Chung, Yoo-Ri
Ha, Kyoung Hwa
Lee, Kihwang
Kim, Dae Jung
Response: Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study (Diabetes Metab J 2019;43:640–8)
title Response: Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study (Diabetes Metab J 2019;43:640–8)
title_full Response: Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study (Diabetes Metab J 2019;43:640–8)
title_fullStr Response: Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study (Diabetes Metab J 2019;43:640–8)
title_full_unstemmed Response: Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study (Diabetes Metab J 2019;43:640–8)
title_short Response: Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study (Diabetes Metab J 2019;43:640–8)
title_sort response: dipeptidyl peptidase-4 inhibitors versus other antidiabetic drugs added to metformin monotherapy in diabetic retinopathy progression: a real world-based cohort study (diabetes metab j 2019;43:640–8)
topic Response
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6943258/
https://www.ncbi.nlm.nih.gov/pubmed/31902152
http://dx.doi.org/10.4093/dmj.2019.0216
work_keys_str_mv AT chungyoori responsedipeptidylpeptidase4inhibitorsversusotherantidiabeticdrugsaddedtometforminmonotherapyindiabeticretinopathyprogressionarealworldbasedcohortstudydiabetesmetabj2019436408
AT hakyounghwa responsedipeptidylpeptidase4inhibitorsversusotherantidiabeticdrugsaddedtometforminmonotherapyindiabeticretinopathyprogressionarealworldbasedcohortstudydiabetesmetabj2019436408
AT leekihwang responsedipeptidylpeptidase4inhibitorsversusotherantidiabeticdrugsaddedtometforminmonotherapyindiabeticretinopathyprogressionarealworldbasedcohortstudydiabetesmetabj2019436408
AT kimdaejung responsedipeptidylpeptidase4inhibitorsversusotherantidiabeticdrugsaddedtometforminmonotherapyindiabeticretinopathyprogressionarealworldbasedcohortstudydiabetesmetabj2019436408

Ejemplares similares